![]() |
市場調查報告書
商品編碼
2089861
腹膜透析市場規模及預測(2021-2034年),全球及區域佔有率、趨勢和成長機會分析報告:按產品、透析類型、適應症、最終用戶和地區分類Peritoneal Dialysis Market Size and Forecast 2021 - 2034, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Offerings, Dialysis Type, Indication, End User, and Geography |
||||||
根據我們最新研究報告《腹膜透析市場預測:按產品、材料、終端用戶和地區分類的全球分析》,該市場預計將從2025年的115.6億美元成長到2034年的215.5億美元,2026年至2034年的複合年成長率為7.2%。腹膜透析市場的成長預計將受到以下因素的推動:末期腎功能衰竭(ESRD)患者群體不斷擴大,而腎臟移植普及率仍然有限;以及保險報銷方案的設計支持居家透析的經濟可行性。
腹膜透析市場正經歷著治療偏好方面的重大結構性轉變,持續性腹膜透析(CAPD)正逐漸被自動化腹膜透析(APD)所取代。這種轉變表明腎臟治療經營模式正在演變,效率和便利性在腎臟治療方案的選擇中變得越來越重要。 APD的市場引入透過創造高附加價值,顯著改變了其經濟格局。具體而言,與傳統CAPD治療中使用的手動換液操作相比,自動化系統的引入提高了每位患者的收入。 APD使用專用透析機以及諸如透析管等耗材,而CAPD僅使用耗材。
除了廣泛應用帶來的商業性效益外,APD(自動腹膜透析)因其諸多優勢而日益受到支持,這些優勢涵蓋了從夜間透析等臨床方面到生活方式調整等諸多方面。這種透析治療方法減少了對患者白天活動的干擾,從而提高了治療依從性。此外,APD使更多患者群體能夠接受治療,包括需要減少職場活動的員工,以及受益於自動化透析循環、無需手動操作設備的年長者,當然也包括CAPD(持續性非臥床腹膜透析)患者。醫療保健系統為促進治療依從性而採取的各項措施也發揮了至關重要的作用,推動了這種治療方法的普及。
目前,醫療衛生系統正經歷重組,住院設施面臨的持續壓力、日益繁重的工作量以及提高長期護理流程經濟效益的需求,正促使人們將關注點轉向慢性病護理的去中心化。在此背景下,腎臟病護理領域的護理管理備受關注。
腹膜透析在促進醫療服務分散化方面發揮著日益重要的作用。這種治療方法允許治療過程從診所轉移到居家照護,同時不影響臨床的連續性或治療效果。當透析中心因對診所和人員的需求不斷成長而持續滿載運轉,且從績效和經濟角度來看擴容不可行時,腹膜透析便成為一種極其有效的解決方案。因此,腹膜透析為患者提供了自我管理的機會,避免了醫院人滿為患,從而提高了醫療系統的效率。腹膜透析可望對醫療系統的效率產生雙重影響。首先,這項技術有助於有效利用醫院資源,因為治療強度較低的病例不再需要佔用醫院資源。其次,透過將透析管理融入以患者為中心的護理,並允許醫療機構進行偶爾的監督,腹膜透析也有助於重新定義醫療服務體系。
全球腹膜透析市場的關鍵洞察和分析觀點源自於腎臟照護監管機構、臨床管治機構和腎臟病研究機構組成的廣泛生態系統。這些機構共同製定治療標準、安全規程和報銷框架。美國食品藥物管理局(FDA) 和歐洲藥品管理局 (EMA) 等機構提供核心法律規範,負責透析設備、透析液和相關醫療技術(包括腹膜透析週期計、導管系統和生物相容性透析液配方)的核准流程。同時,國際標準化組織 (ISO) 等國際標準化框架制定了透析液、設備製造和感染控制規程的品質和安全標準,確保全球供應鏈的一致性。
According to our new research study on "Peritoneal Dialysis Market Forecast to 2034 Global Analysis - by product, material, end user and Geography," the market is anticipated to grow from US$ 11.56 billion in 2025 and is projected to reach US$ 21.55 billion by 2034; it is expected to register a CAGR of 7.2% during 2026-2034. The peritoneal dialysis market growth has anticipated owing to expansion of ESRD treatment pool with limited transplant penetration as well as reimbursement design favoring home dialysis economics.
The peritoneal dialysis market is experiencing a pronounced structural shift in terms of modality preferences taking place in the peritoneal dialysis market in favor of moving away from the utilization of CAPD to APD. This change indicates a growing evolution of the business model within renal therapy provision that involves the importance of factors such as efficiency and convenience in making decisions about renal therapy choice. The introduction of APD into the market is significantly changing its economics through the creation of a high-value proposition, whereby the use of the automated system leads to higher per-patient revenue than the traditional manual exchange procedure utilized in CAPD therapy. APD involves the utilization of dedicated dialysis machines that work alongside consumable items such as tubing, while CAPD uses only consumable products.
Apart from the commercial benefits that have made it popular, APD has become increasingly favored for its advantages that range from clinical aspects to lifestyle adjustments, including the ability to undertake dialysis at night time. With such a way of conducting dialysis treatment, there will be fewer interruptions during the day when the patient can go about their regular activities, leading to greater adherence to treatment among other things. In addition to this, APD has allowed a broader population of patients to undertake treatment in addition to CAPD patients, which include employees who need to minimize their involvement in workplace activities as well as senior citizens who would benefit from automated dialysis cycles which will reduce their manual engagement with the equipment. There have been health systems interventions in favor of treatment adherence which have played an important role in making this treatment modality popular.
There is currently restructuring being carried out in healthcare systems where the focus has shifted towards de-centralized chronic disease care due to constant pressure on in-patient facilities coupled with increased workloads as well as the need to become more economical along the line of lengthy care processes. In this respect, care management in the renal domain has come to the forefront.
Peritoneal dialysis is becoming more relevant for the implementation of the decentralization agenda through the provision of peritoneal dialysis treatment. This treatment method is capable of shifting the treatment processes from the clinic setting to home care without compromising the clinical continuity and effectiveness of procedures performed. Peritoneal dialysis is highly applicable in situations where dialysis centers face constant saturation due to an increase in the demand for the services of clinics and staff, and extending their capacities is not feasible in terms of both performance and economics. Thus, through peritoneal dialysis treatments, patients can be provided with an opportunity to manage themselves and avoid overcrowding of hospitals and, therefore, improve the efficiency of the system. Peritoneal dialysis can have a twofold impact on the health system efficiency. First, this technique contributes to the better use of hospital facilities since low-intensity cases will no longer require such resources. On the other hand, peritoneal dialysis can help redefine the system of medical care delivery as dialysis management becomes integrated into patient-centered care with occasional supervision performed by the provider organization.
Key insights and analytical perspectives on the global peritoneal dialysis market are derived from a broad ecosystem of renal care regulatory authorities, clinical governance bodies, and nephrology-focused research organizations that collectively shape treatment standards, safety protocols, and reimbursement frameworks. Core regulatory oversight is provided by agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), which govern approval pathways for dialysis devices, solutions, and associated medical technologies, including peritoneal dialysis cyclers, catheter systems, and biocompatible dialysate formulations. In parallel, international standardization frameworks such as the International Organization for Standardization (ISO) establish quality and safety benchmarks for dialysis fluids, equipment manufacturing, and infection control protocols, ensuring consistency across global supply chains.